Christine van Heek Net Worth

The estimated Net Worth of Heek Christi Van is at least $338 Mille dollars as of 6 June 2022. Ms. Van owns over 10,526 units of Concert Pharmaceuticals Inc stock worth over $214,699 and over the last 8 years she sold CNCE stock worth over $0. In addition, she makes $122,941 as Independent Director at Concert Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Heek CNCE stock SEC Form 4 insiders trading

Christine has made over 2 trades of the Concert Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she bought 10,526 units of CNCE stock worth $49,999 on 6 June 2022.

The largest trade she's ever made was buying 10,526 units of Concert Pharmaceuticals Inc stock on 6 June 2022 worth over $49,999. On average, Christine trades about 2,053 units every 104 days since 2016. As of 6 June 2022 she still owns at least 25,651 units of Concert Pharmaceuticals Inc stock.

You can see the complete history of Ms. Van stock trades at the bottom of the page.

Christine van Heek biography

Christine van Heek is an Independent Director of Concert Pharmaceuticals Inc. Ms. van Heek has served as a member of our Board since April 2016. Ms. van Heek has served as an adviser and consultant to several companies in the biopharmaceutical industry. From 1991 to 2003, Ms. van Heek served in various roles at Genzyme Corporation, a biotechnology company, including as Corporate Officer and President, Therapeutics Division; General Manager, Renal Division; and Vice President, Global Marketing. In addition, she has held various sales and marketing positions at Genentech, Inc. and Caremark/HHCA. Ms. van Heek received a B.S.N. from the University of Iowa and an M.B.A. from Lindenwood University in St. Louis.

What is the salary of Christine Heek?

As the Independent Director of Concert Pharmaceuticals Inc, the total compensation of Christine Heek at Concert Pharmaceuticals Inc is $122,941. There are 11 executives at Concert Pharmaceuticals Inc getting paid more, with Roger Tung having the highest compensation of $2,772,350.

How old is Christine Heek?

Christine Heek is 63, she's been the Independent Director of Concert Pharmaceuticals Inc since 2016. There are 5 older and 9 younger executives at Concert Pharmaceuticals Inc. The oldest executive at Concert Pharmaceuticals Inc is Peter Hutt, 85, who is the Independent Director.

What's Christine Heek's mailing address?

Heek's mailing address filed with the SEC is C/O CONCERT PHARMACEUTICALS, INC., 65 HAYDEN AVENUE, SUITE 3000N, LEXINGTON, MA, 02421.

Insiders trading at Concert Pharmaceuticals Inc

Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over $69,766,120 worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth $25,219,472 . The most active insiders traders include Plc Gsk, Associates Gp Llcqvt Fund V... e Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of $447,820. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth $50,380.

What does Concert Pharmaceuticals Inc do?

Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.

Complete history of Ms. Van stock trades at Concert Pharmaceuticals Inc

Concert Pharmaceuticals Inc executives and stock owners

Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Roger Tung,
  President, Chief Executive Officer, Co-Founder, Director
• Nancy Stuart,
  Chief Operating Officer
• Marc Becker,
  Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
• James Cassella,
  Chief Development Officer
• Dr. Roger D. Tung,
  Co-Founder, CEO, Pres & Exec. Director
• Dr. James V. Cassella,
  Chief Devel. Officer
• Jesper Hoiland,
  Independent Director
• Richard Aldrich,
  Independent Chairman of the Board, Co-Founder
• Thomas Auchincloss,
  Independent Director
• Ronald Barrett,
  Independent Director
• Peter Hutt,
  Independent Director
• Christine van Heek,
  Independent Director
• Wilfred Jaeger,
  Independent Director
• Richard H. Aldrich M.B.A., Mba,
  Co-Founder & Chairman
• Justine Koenigsberg,
  Senior Vice President, Corporate Communications and Investor Relations
• Jeffrey Munsie,
  Chief Legal Officer, Secretary
• Christine Boisclair,
  Sr. VP of Regulatory Affairs & Quality Assurance
• Dr. Nabil Uddin Pharm.D.,
  VP of Corp. Devel.
• Jeffrey A. Munsie,
  Chief Legal Officer & Corp. Sec.
• Marc A. Becker,
  CFO & Principal Accounting Officer
• Nancy Stuart,
  Chief Operating Officer
• Wendall Wierenga,
  Director
• Wilfred Ethree Arch Managem...,
  
• Pauline Mc Gowan,
  VP, Finance
• D. Ryan Daws,
  Chief Financial Officer
• Robert Silverman,
  Senior VP, General Counsel
• Meghan Fitzgerald,
  Director
• Lynette Herscha,
  General Counsel
• Heek Christi Van,
  Director
• Ryan Lynch,
  PAO
• Partners L P/Ilbiotechnolog...,
  
• Leaf Ventures I, L.P.New Le...,
  
• Helmut Schuhsler,
  Director
• John Gordon Freund,
  Director
• Associates Gp Llcqvt Fund V...,
  
• Capital Management Llcbrook...,
  
• Ventures Fund 2004 L P Flag...,
  
• Plc Gsk,
  
• Capital Partners, L.P.Adage...,
  
• Venture Partners Qualified ...,
  
• Life Science Ventures Vi Gm...,
  
• Arch Management Iv, L.L.C.J...,
  
• Arch Management Iii Llcthre...,
  
• Arch Management Iv, L.L.C.J...,
  
• Xii Gp Llc Greylock Xii Lim...,
  
• Arch Management Iii Llcjaeg...,
  
• Jesper Hoeiland,
  Director
• Marc A. Becker,
  Chief Financial Officer